Prognostic factors of brain metastases from breast cancer: Impact oftargeted therapies

Breast

Volumn 22, Issue 5, 2013, Pages 993-998

  Braccini, Antoine Laurent ^a   Azria, David ^a   Thezenas, Simon ^a   Romieu, Gilles ^a   Ferrero, Jean Marc ^b   Jacot, William ^a  

^a CENTRE VAL D AURELLE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Brain metastases; Breast cancer; HER2; Prognostic factors; Targeted therapies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HORMONE RECEPTOR POSITIVE EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; HUMAN; INTRACRANIAL HYPERTENSION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RECURSIVE PARTITIONING ANALYSIS; TRIPLE NEGATIVE BREAST CANCER;

BRAIN METASTASES; BREAST CANCER; HER2; PROGNOSTIC FACTORS; TARGETED THERAPIES;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTRACRANIAL HYPERTENSION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; QUINAZOLINES; RADIOSURGERY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84884133064     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.05.011     Document Type: Article

References (36)

1. Chang E.L., Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003, 8(5):398-410.
2. Biswas Brain metastasis: evidence-based management. JCancer Res Ther 2006, 2(1):5-13.
3. Weil R.J., Palmieri D.C., Bronder J.L., Stark A.M., Steeg P.S. Breast cancer metastasis to the central nervous system. Am J Pathol 2005, 167(4):913-920.
4. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. JClin Oncol 2009, 27(31):5278-5286.
5. Shmueli E., Wigler N., Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004, 40(3):379-382.
6. Lower E.E., Drosick D.R., Blau R., Brennan L., Danneman W., Hawley D.K. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003, 4(2):114-119.
7. Kirsch D.G., Ledezma C.J., Mathews C.S., Bhan A.K., Ancukiewicz M., Hochberg F.H., et al. Survival after brain metastases from breast cancer in the trastuzumab era. JClin Oncol 2005, 23(9):2114-2116. author reply 2116-7.
8. Bartsch R., Rottenfusser A., Wenzel C., Dieckmann K., Pluschnig U., Altorjai G., et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. JNeurooncol 2007, 85(3):311-317.
9. Sperduto P.W., Kased N., Roberge D., Xu Z., Shanley R., Luo X., et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2011, 82(5):2111-2117.
10. Nam B.H., Kim S.Y., Han H.S., Kwon Y., Lee K.S., Kim T.H., et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008, 10(1):R20.
11. Eichler A.F., Kuter I., Ryan P., Schapira L., Younger J., Henson J.W. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008, 112(11):2359-2367.
12. Niwinska A., Murawska M., Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010, 21(5):942-948.
13. Dawood S., Gonzalez-Angulo A.M., Albarracin C., Yu T.K., Hortobagyi G.N., Buchholz T.A., et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 2010, 116(13):3084-3092.
14. Arslan U.Y., Oksuzoglu B., Aksoy S., Harputluoglu H., Turker I., Ozisik Y., et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast 2011, 20(6):562-567.
15. Berghoff A., Bago-Horvath Z., De Vries C., Dubsky P., Pluschnig U., Rudas M., et al. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 2012, 106(3):440-446.
16. Le Scodan R., Jouanneau L., Massard C., Gutierrez M., Kirova Y., Cherel P., et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 2012, 11:395.
17. Pestalozzi B.C., Zahrieh D., Price K.N., Holmberg S.B., Lindtner J., Collins J., et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17(6):935-944.
18. Heitz F., Harter P., Lueck H.J., Fissler-Eckhoff A., Lorenz-Salehi F., Scheil-Bertram S., et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009, 45(16):2792-2798.
19. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., et al. Metastatic behavior of breast cancer subtypes. JClin Oncol 2010, 28(20):3271-3277.
20. Anders C.K., Deal A.M., Miller C.R., Khorram C., Meng H., Burrows E., et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2010, 117(8):1602-1611.
21. Morris P.G., Murphy C.G., Mallam D., Accordino M., Patil S., Howard J., et al. Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J 2012, 18(4):345-350.
22. Xu Z., Schlesinger D., Toulmin S., Rich T., Sheehan J. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases. Int J Radiat Oncol Biol Phys 2012, 84(3):612-618.
23. Rosner D., Nemoto T., Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986, 58(4):832-839.
24. Boogerd W., Dalesio O., Bais E.M., van der Sande J.J. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992, 69(4):972-980.
25. Franciosi V., Cocconi G., Michiara M., Di Costanzo F., Fosser V., Tonato M., et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999, 85(7):1599-1605.
26. Jacot W., Gerlotto-Borne M.C., Thezenas S., Pouderoux S., Poujol S., About M., et al. Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer 2010, 10:257.
27. Lee S.S., Ahn J.H., Kim M.K., Sym S.J., Gong G., Ahn S.D., et al. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat 2008, 111(3):523-530.
28. Kelly P.J., Lin N.U., Claus E.B., Quant E.C., Weiss S.E., Alexander B.M. Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors. Cancer 2011, 118(8):2014-2020.
29. Matsunaga S., Shuto T., Kawahara N., Suenaga J., Inomori S., Fujino H. Gamma knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype. JNeurosurg 2010, 113(Suppl):65-72.
30. Gondi V., Tome W.A., Mehta M.P. Why avoid the hippocampus? A comprehensive review. Radiother Oncol 2010, 97(3):370-376.
31. Church D.N., Modgil R., Guglani S., Bahl A., Hopkins K., Braybrooke J.P., et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008, 31(3):250-254.
32. Dawood S., Broglio K., Esteva F.J., Ibrahim N.K., Kau S.W., Islam R., et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008, 19(7):1242-1248.
33. Park I.H., Ro J., Lee K.S., Nam B.H., Kwon Y., Shin K.H. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009, 20(1):56-62.
34. Bachelot T. LANDSCAPE: an FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). JClin Oncol 2011, 29. (suppl; abstr 509) 2011.
35. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18(1):23-28.
36. Bartsch R., Berghoff A., Pluschnig U., Bago-Horvath Z., Dubsky P., Rottenfusser A., et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012, 106(1):25-31.